“…Several SRPK1/2-related roles in cancer have been reported, such as angiogenesis (Gammons et al, 2014), proliferation (Jang et al, 2008), cell migration and EMT (Wang et al, 2017), metastasis (van Roosmalen et al, 2015Zhuo et al, 2018), lipid biosynthesis (Lee et al, 2017), genome stability maintenance (Sridhara et al, 2017), and drug resistance mediation (Wang et al, 2019). We previously demonstrated the anti-metastatic effect of pharmacological inhibitors targeting the SRPK1/2 family in melanoma (Gammons et al, 2014;Moreira et al, 2018;Moreira et al, 2022). As selective SRPK pharmacological inhibitors are still unknown, the role of SRPK1 or SRPK2 activity in melanoma remains obscure.…”